Search Results - "ROOT, Michael J"

Refine Results
  1. 1

    Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer by Khasnis, Mukta D, Halkidis, Konstantine, Bhardwaj, Anshul, Root, Michael J

    Published in PLoS pathogens (19-12-2016)
    “…Structural rearrangements of HIV-1 glycoprotein Env promote viral entry through membrane fusion. Env is a symmetric homotrimer with each protomer composed of…”
    Get full text
    Journal Article
  2. 2

    Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env by Schapiro, Hannah M, Khasnis, Mukta D, Ahn, Koree, Karagiaridi, Alexandra, Hayden, Stephanie, Cilento, Maria E, Root, Michael J

    Published in PLoS pathogens (01-05-2022)
    “…Glycoprotein Env of human immunodeficiency virus type 1 (HIV-1) mediates viral entry through membrane fusion. Composed of gp120 and gp41 subunits arranged as a…”
    Get full text
    Journal Article
  3. 3

    Design of a Potent d-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance by WELCH, Brett D, FRANCIS, J. Nicholas, ROOT, Michael J, KAY, Michael S, REDMAN, Joseph S, PAUL, Suparna, WEINSTOCK, Matthew T, REEVES, Jacqueline D, LIE, Yolanda S, WHITBY, Frank G, ECKERT, Debra M, HILL, Christopher P

    Published in Journal of Virology (01-11-2010)
    “…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  4. 4

    Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators by Zhang, Shiyu, Holmes, Andrew P, Dick, Alexej, Rashad, Adel A, Enríquez Rodríguez, Lucía, Canziani, Gabriela A, Root, Michael J, Chaiken, Irwin M

    Published in Retrovirology (09-10-2021)
    “…We previously developed drug-like peptide triazoles (PTs) that target HIV-1 Envelope (Env) gp120, potently inhibit viral entry, and irreversibly inactivate…”
    Get full text
    Journal Article
  5. 5

    Interactions of HIV-1 Inhibitory Peptide T20 with the gp41 N-HR Coiled Coil by Champagne, Kelly, Shishido, Akira, Root, Michael J.

    Published in The Journal of biological chemistry (06-02-2009)
    “…Cellular entry of human immunodeficiency virus type 1 (HIV-1) involves fusion of viral and cellular membranes and is mediated by structural transitions in…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Characterization of resistance to a potent D-peptide HIV entry inhibitor by Smith, Amanda R, Weinstock, Matthew T, Siglin, Amanda E, Whitby, Frank G, Francis, J Nicholas, Hill, Christopher P, Eckert, Debra M, Root, Michael J, Kay, Michael S

    Published in Retrovirology (22-10-2019)
    “…PIE12-trimer is a highly potent D-peptide HIV-1 entry inhibitor that broadly targets group M isolates. It specifically binds the three identical conserved…”
    Get full text
    Journal Article
  8. 8

    Kinetic Dependence to HIV-1 Entry Inhibition by Steger, H. Kirby, Root, Michael J.

    Published in The Journal of biological chemistry (01-09-2006)
    “…Infection by human immunodeficiency virus type 1 (HIV-1) involves the fusion of viral and cellular membranes mediated by formation of the gp41…”
    Get full text
    Journal Article
  9. 9

    Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding by Kahle, Kristen M, Steger, H Kirby, Root, Michael J

    Published in PLoS pathogens (01-11-2009)
    “…Both equilibrium and nonequilibrium factors influence the efficacy of pharmaceutical agents that target intermediate states of biochemical reactions. We…”
    Get full text
    Journal Article
  10. 10

    Nucleoporin Nup50 Stabilizes Closed Conformation of Armadillo repeat 10 in Importin α5 by Pumroy, Ruth A., Nardozzi, Jonathan D., Hart, Darren J., Root, Michael J., Cingolani, Gino

    Published in The Journal of biological chemistry (13-01-2012)
    “…The human genome encodes six isoforms of importin α that show greater than 60% sequence similarity and remarkable substrate specificity. The isoform importin…”
    Get full text
    Journal Article
  11. 11

    Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain by Adekar, Sharad P, Takahashi, Tsuyoshi, Jones, R Mark, Al-Saleem, Fetweh H, Ancharski, Denise M, Root, Michael J, Kapadnis, B P, Simpson, Lance L, Dessain, Scott K

    Published in PloS one (20-08-2008)
    “…Botulinum neurotoxins (BoNT) are a family of category A select bioterror agents and the most potent biological toxins known. Cloned antibody therapeutics hold…”
    Get full text
    Journal Article
  12. 12

    Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors by Ahn, Koree W., Root, Michael J.

    Published in The Journal of biological chemistry (06-10-2017)
    “…The homotrimeric HIV-1 envelope glycoprotein (Env) undergoes receptor-triggered structural changes that mediate viral entry through membrane fusion. This…”
    Get full text
    Journal Article
  13. 13

    Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins by Adekar, Sharad P., Jones, R. Mark, Elias, M.D., Al-Saleem, Fetweh H., Root, Michael J., Simpson, Lance L., Dessain, Scott K.

    Published in Journal of immunological methods (20-04-2008)
    “…The affinity-matured human antibody repertoire may be ideal as a source for antibody therapeutics against infectious diseases and bioterror agents. Hybridoma…”
    Get full text
    Journal Article
  14. 14

    Polyvalent Side Chain Peptide–Synthetic Polymer Conjugates as HIV-1 Entry Inhibitors by Danial, Maarten, Root, Michael J., Klok, Harm-Anton

    Published in Biomacromolecules (14-05-2012)
    “…This report describes the synthesis and properties of a series of polyvalent side chain peptide–synthetic polymer conjugates designed to block the CD4 binding…”
    Get full text
    Journal Article
  15. 15

    Targeting Therapeutics to an Exposed and Conserved Binding Element of the HIV-1 Fusion Protein by Root, Michael J., Hamer, Dean H.

    “…There is an urgent need for new drugs that can kill HIV type 1 (HIV-1)-infected cells. HIV-1 glycoprotein Env, which promotes viral membrane fusion through…”
    Get full text
    Journal Article
  16. 16

    Lithium–manganese dioxide cells for implantable defibrillator devices—Discharge voltage models by Root, Michael J.

    Published in Journal of power sources (01-08-2010)
    “…The discharge potential behavior of lithium-manganese dioxide cells designed for implantable cardiac defibrillators was characterized as a function of extent…”
    Get full text
    Journal Article
  17. 17

    Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV‑1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity by Danial, Maarten, Stauffer, Angela N, Wurm, Frederik R, Root, Michael J, Klok, Harm-Anton

    Published in Bioconjugate chemistry (15-03-2017)
    “…A popular strategy for overcoming the limited plasma half-life of peptide heptad repeat 2 (HR2) fusion inhibitors against HIV-1 is conjugation with…”
    Get full text
    Journal Article
  18. 18

    Protein Design of an HIV-1 Entry Inhibitor by Root, Michael J., Kay, Michael S., Kim, Peter S.

    “…Human immunodeficiency virus type-1 (HIV-1) membrane fusion is promoted by the formation of a trimer-of-hairpins structure that brings the amino- and…”
    Get full text
    Journal Article
  19. 19

    Implantable Cardiac Rhythm Device Batteries by Root, Michael J.

    “…Batteries used for implantable cardiac rhythm devices are described herein. Fully implanted cardiac rhythm devices, pacemakers, and defibrillators treat…”
    Get full text
    Journal Article
  20. 20

    HIV-1 gp41 as a target for viral entry inhibition by Root, Michael J, Steger, H Kirby

    Published in Current pharmaceutical design (01-01-2004)
    “…The recent success of the fusion inhibitor T-20 (enfuvirtide) in clinical studies has ushered in a new chapter in the development of anti-HIV-1 therapeutics…”
    Get more information
    Journal Article